Clinical Trial

Gender Differences in Gastric Cancer Care and Its Adherence to Guidelines in Germany

Study acronym: MaGen
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 17, 2025 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Background: Gastric cancer is the fifth most common cancer globally and the fourth leading cause of cancer-related mortality. While gender differences in gastric cancer care are underexplored in Germany, international studies have revealed disparities in aspects such as histology, co-morbidities, treatment approaches, and survival outcomes. This study aims to explore gender-specific variations in clinical management and their impact on mortality, complications, and survival rates in gastric carcinoma patients in Germany. Methods: This nationwide, retrospective cohort study will analyze data from the German Diagnosis-Related Group statistic and regional clinical cancer registries from 2017 to 2021. The study will evaluate both datasets separately, providing a comprehensive view of gender differences in gastric cancer care. Primary outcomes include hospital mortality and survival rates, while secondary endpoints include surgical complications, treatment modalities, and postoperative outcomes. The analysis will investigate whether gender influences tumor characteristics, access to treatment, and therapy effectiveness. Statistical methods such as descriptive analysis, regression models, and survival analysis will be applied to identify gender-related variations in diagnosis, treatment, and outcomes. Discussion: By identifying potential gender disparities in diagnosis, treatment, and outcomes, the findings may inform revisions to clinical guidelines and support the development of more personalized treatment strategies. This study aims to improve the quality of care for gastric cancer patients and promote more individualized, sex-sensitive medical practices.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-23.
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-09-16
Trial Details
NCT Number NCT06902337
Lead Sponsor Medizinische Hochschule Brandenburg Theodor Fontane
Conditions Gastric Adenocarcinoma
Enrollment 75,000 participants
Start Date 2025-07-31
Primary Completion 2026-04-30 (estimated)
Study Completion 2026-04-30 (estimated)
Updated on ClinicalTrials.gov 2025-09-17